CD56 詳細
Molecule Name
Neural cell adhesion molecule 1
分子の別称
CD56
Drug Development Progress
治験薬の数6
市販薬剤の数0
研究＆開発段階Phase 2 Clinical
ターゲットの別称
Neural cell adhesion molecule 1，CD56，NCAM1，NCAM，Neural Cell Adhesion Molecule， NCAM，CD56 Antigen，N-CAM-1，MSK39，NCAM-1，Antigen Recognized By Monoclonal Antibody 5.1H11
CD56 製品リスト
You Have Viewed 0 Of 0 Results
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Lorvotuzumab mertansine | BB-10901; IMGN-901; huN-901-DM1; IMGN-901-TAP; huN-901-SPP-DM1 | Phase 2 Clinical | Immunogen Inc | Carcinoma, Merkel Cell; Leukemia; Multiple Myeloma; Neuroblastoma; Neurofibrosarcoma; Ovarian Neoplasms; Pulmonary Blastoma; Rhabdomyosarcoma; Sarcoma, Synovial; Small Cell Lung Carcinoma; Wilms Tumor | 詳細 |
| EB-DART-NK01 | EB-DART-NK01 | Phase 2 Clinical | Beijing Biotech | Small Cell Lung Carcinoma | 詳細 |
| CUBT-906 | CUBT-906 | Phase 2 Clinical | Curative Biotechnology Inc | Glioblastoma | 詳細 |
| GD2/CD56 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR GD2/CD56 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | 詳細 |
| IN-B015 | IN-B-015; IN-B00004 | Phase 1 Clinical | HK inno.N Corporation | Neoplasms | 詳細 |
| DXC-006 | DXC-006; DAC-006 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Hematologic Neoplasms; Lung Neoplasms; Solid tumours | 詳細 |